Director Paul Stuka filed a Form 4 with the SEC on November 17, 2026, disclosing a purchase of 307,693 shares of InspireMD, Inc. common stock on November 13, 2026, through Osiris Investment Partners, L.P. in the company's underwritten public offering at $0.65 per share.

Key Highlights

  • Transaction date: November 13, 2026, with 307,693 shares of common stock acquired at $0.65 per share via Osiris Investment Partners, L.P.
  • Accompanying warrants: 230,769 Series L common stock warrants were also acquired through the same public offering at a combined public offering price of $0.65 per share and accompanying warrants.
  • Warrant terms: Series L warrants are immediately exercisable at $0.65 per share and expire on November 16, 2027, according to the filing.
  • Post-transaction beneficial ownership: Following the reported transaction, Stuka is reported as indirectly beneficially owning 731,397 shares of common stock and 230,769 Series L warrants, all held through Osiris.
  • Indirect ownership: All reported securities are held by Osiris; Stuka serves as managing member of Osiris Partners, LLC, the general partner of Osiris, and disclaims beneficial ownership except to the extent of his pecuniary interest.
  • Issuer: InspireMD, Inc., trading on NASDAQ:NSPR.

Stuka's Public Offering Purchase and Warrant Acquisition at InspireMD

According to the Form 4 filed November 17, 2026, Paul Stuka, a director of InspireMD, Inc. (NASDAQ:NSPR), reported a transaction dated November 13, 2026. The filing discloses that 307,693 shares of InspireMD common stock were acquired through Osiris Investment Partners, L.P. at a price of $0.65 per share. The filing states this purchase was made in the issuer's underwritten public offering at "a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants."

In connection with the same transaction, the filing reports that 230,769 Series L common stock warrants were acquired through Osiris, also at a price of $0.00 for the derivative security itself, with an exercise price of $0.65 per share. The warrants became exercisable immediately upon issuance on November 13, 2026, and are set to expire on November 16, 2027, per the filing. Both the shares and the warrants are held indirectly through Osiris, as Stuka serves as managing member of Osiris Partners, LLC, the general partner of Osiris.

The filing also notes that 667,871 shares are listed in Table I as directly owned (column D), with no transaction effected, and are included "for informational purposes only." Stuka, through Osiris, is reported as beneficially owning 731,397 shares of common stock and 230,769 Series L warrants following the reported transaction. The filing includes a disclaimer that Stuka "disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein." The Form 4 was signed by Michael Lawless as attorney-in-fact for Paul Stuka on November 17, 2026.

What Was Disclosed

InspireMD director Paul Stuka filed a Form 4 reporting the acquisition of 307,693 shares of common stock and 230,769 Series L warrants through Osiris Investment Partners, L.P. in the company's underwritten public offering on November 13, 2026, at $0.65 per unit.